Patheon sells off its Mexican division for $34M

Contract drug developer Patheon has flipped its Mexican operations to Perrigo ($PRGO) for $34 million in cash, shifting its focus to the U.S. and Europe. Under the deal, Perrigo gets Patheon's softgel manufacturing and formulation capacity in Mexico. Patheon, part of the DPx conglomerate, has been investing elsewhere in North America, this week spending about $3 million to expand a North Carolina testing facility. Sale | Expansion